Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: Experience of two US centres

Haemophilia

Volumn 21, Issue 3, 2015, Pages 365-373

  Nakar, C ^a   Manco Johnson, M J ^b   Lail, A ^c   Donfield, S ^c   Maahs, J ^a   Chong, Y ^a   Blades, T ^b   Shapiro, A ^a  

^a Indiana Hemophilia and Thrombosis Center   (United States)

^b Mountain States Regional Hemophilia and Thrombosis Center   (United States)

^c RHO INC   (United States)

Author keywords

Factor VIII; Haemophilia A; Immune tolerance induction; Inhibitors; Time interval; Titre

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; IMMUNOGLOBULIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR;

ARTICLE; CATHETER INFECTION; CHILD; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RECURRENT INFECTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADULT; BLOOD; COMPLICATION; GENETICS; IMMUNOLOGY; INFANT; MUTATION; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INFANT; ISOANTIBODIES; MUTATION; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84928824959     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12608     Document Type: Article

References (40)

1. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
2. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998; 4: 68.
3. Viel KR, Ameri A, Abshire TC et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-27.
4. Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 2010; 16: 66-70.
5. Chambost H. Assessing risk factors: prevention of inhibitors in haemophilia. Haemophilia 2010; 16(Suppl 2): 10-5.
6. Maclean PS, Richards M, Williams M et al. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2011; 17: 282-7.
7. Hay CR, Palmer B, Chalmers E et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
8. Eckhardt CL, van der Bom JG, van der Naald M, Peters M, Kamphuisen PW, Fijnvandraat K. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost 2011; 9: 1948-58.
9. Carpenter SL, Michael Soucie J, Sterner S, Presley R; Investigators HTCNH. Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemophilia 2012; 18: e260-5.
10. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients-long-term follow-up and continuing experience. Haemophilia 2012; 18: e18-20.
11. Gouw SC, van den Berg HM, Oldenburg J et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119: 2922-34.
12. Gouw SC, van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
13. Dimichele D. Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence-based approach. J Thromb Haemost 2007; 5(Suppl 1): 143-50.
14. Di Minno G, Coppola A. Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution? Haemophilia 2013; 19(Suppl 1): 18-23.
15. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
16. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 436-63.
17. Benson G, Auerswald G, Elezovic I et al. Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. Eur J Haematol 2012; 88: 371-9.
18. DiMichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl 1): 1-22.
19. Kempton CL, White GC. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009; 113: 11-7.
20. Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
21. Makris M, Hay CR, Gringeri A, D'Oiron R. How I treat inhibitors in haemophilia. Haemophilia 2012; 18(Suppl 4): 48-53.
22. Collins PW, Chalmers E, Hart DP et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160: 153-70.
23. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thromb Haemost 1994; 72: 155-8.
24. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77(Suppl 1): 33-7.
25. Lenk H, Group IS. The German Registry of immune tolerance treatment in hemophilia-1999 update. Haematologica 2000; 85: 45-7.
26. Haya S, López MF, Aznar JA, Batlle J, Group SIT. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia 2001; 7: 154-9.
27. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
28. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
29. Coppola A, Margaglione M, Santagostino E et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
30. DiMichele DM. Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication. Pediatr Blood Cancer 2013; 60(Suppl 1): S30-3.
31. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
32. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008; 29: 848-62.
33. Schmetterer KG, Neunkirchner A, Pickl WF. Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB J 2012; 26: 2253-76.
34. Kasper CK, Aledort L, Aronson D et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
35. Mariani G, Kroner B. (ITSG) ITSG. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
36. Rivard GE, Rothschild C, Toll T, Achilles K. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study. Haemophilia 2013; 19: 449-55.
37. Kreuz W, Ehrenforth S, Funk M et al. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia 1995; 1: 24-32.
38. Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev 2003; 196: 125-46.
39. Chu VT, Berek C. The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev 2013; 251: 177-88.
40. Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly - TFH cells in human health and disease. Nat Rev Immunol 2013; 13: 412-26.